Early Identification of Progressive Pulmonary Fibrosis, Precision Medicine for More Oxygen - ILD Extension.

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

The goal of this observational study is to identify early biomarkers that can predict the development of progressive pulmonary fibrosis (PPF) in participants with interstitial lung diseases (ILDs). The participant population includes adults diagnosed with idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), other fibrotic ILDs, and interstitial lung abnormalities (ILA). The main questions it aims to answer are: * What biomarkers and risk factors are linked to fibrosis progression or can predict rapid worsening and sudden flare-ups in IPF and FPF patients? * What biomarkers and risk factors can predict the development of a PPF phenotype in different types of ILD? * What biomarkers and risk factors can help identify ILA patients who may develop significant ILD? * What biomarkers and risk factors can predict how well ILD patients will respond to treatment? Researchers will compare the outcomes between participants diagnosed with IPF/FPF, other fibrotic ILDs, and ILA to see if early detection biomarkers differ among these groups. Participants will: * Undergo blood sampling. * Perform lung function tests. * Have CT scans. * Perform breath analysis * Participate in exposome and microbiome analyses. * Complete questionnaires. * A subgroup of participants will be offered bronchoscopy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Diagnosis of (1) idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), (2) other fibrotic ILDs (fILD), including fibrotic hypersensitivity pneumonitis (fHP), idiopathic non-specific interstitial pneumonia (iNSIP), connective tissue disease (CTD)-ILD, and unclassifiable ILD (uILD); or (3) interstitial lung abnormalities (ILA).

• Meeting all the following criteria during the screening period:

‣ FVC ≥45% predicted.

⁃ FEV1/FVC ≥0.7.

⁃ DLco corrected for Hb ≥40% predicted.

• Able to provide written informed consent as approved by the independent ethics committee.

• Able to undergo a CT scan and perform PFT.

• Age \> 18 years and \< 80 years.

• Understanding of the Dutch or English language.

Locations
Other Locations
Netherlands
Amsterdam UMC, locatie VUmc
RECRUITING
Amsterdam
Contact Information
Primary
Jan Willem Duitman, PhD
j.w.duitman@amsterdamumc.nl
0205668753
Backup
Iris Simons, MD
i.simons@amsterdamumc.nl
0205668753
Time Frame
Start Date: 2024-11-01
Estimated Completion Date: 2031-10-01
Participants
Target number of participants: 450
Treatments
Idiopathic Pulmonary Fibrosis/Familial Pulmonary Fibrosis
fibrotic ILD
Patients with a diagnosis of: chronic Hypersensitivity Pneumonitis (cHP), unclassifiable ILD (uILD), idiopathic NSIP or CTD-ILD.
Interstitial Lung Abnormalities
Sponsors
Collaborators: Boehringer Ingelheim, AbbVie
Leads: Amsterdam UMC, location VUmc

This content was sourced from clinicaltrials.gov